CRL · Charles River Laboratories International, Inc.
$280.05
-1.22 (-0.43%)
At close · Aug 14
Market Cap
$13.37B
Shares
47.74M
Charles River Laboratories International, Inc. Earnings Call Transcripts
Every quarterly earnings call for Charles River Laboratories International, Inc. (CRL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲10.4%
$989.16M
$96.47M
'22 Q3
22-11-02
▲21.5%
$1.10B
$187.41M
'22 Q4
23-02-22
▲12.6%
$1.03B
$103.13M
'23 Q1
23-05-11
▲8.9%
$1.06B
$97.02M
'23 Q2
23-08-09
▲3.8%
$1.03B
$87.39M
'23 Q3
23-11-08
▼7.9%
$1.01B
$187.08M
'23 Q4
24-02-14
▼1.7%
$1.01B
$72.96M
'24 Q1
24-05-09
▼3.2%
$1.03B
$94.08M
'24 Q2
24-08-07
▼1.6%
$1.01B
$69.66M
'24 Q3
24-11-06
▼1.1%
$1.00B
−$214.50M
'24 Q4
25-02-19
▼2.7%
$984.17M
$25.47M
'25 Q1
25-05-07
▲0.6%
$1.03B
$52.33M
'25 Q2
25-08-06
▼0.5%
$1.00B
$54.42M
'25 Q3
25-11-05
▼0.8%
$994.23M
−$276.56M
'25 Q4
26-02-18
▲1.2%
$995.83M
−$14.84M
'26 Q1
26-05-07
LATEST
▼2.7%
$1.00B
−$1.48M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Charles River Laboratories International, Inc. Q2 FY2026 Earnings Call
Revenue
$1.00B
▼ 2.7% YoY Diluted EPS
$-0.03
▼ 102.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Charles River Laboratories at the Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
Charles River Laboratories at the William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Charles River Laboratories International, Inc. Q1 FY2026 Earnings Call
Positive tone
Biotech and large pharma demand environment
Safety Assessment / DSA segment and NHP supply
Cost savings and operating efficiency
Revenue
$995.83M
▲ 1.2% YoY Diluted EPS
$-0.30
▼ 160% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-18
Charles River Laboratories International, Inc. Q4 FY2025 Earnings Call
Balanced tone
CEO Transition and Leadership Change
NHP Supply Chain and KF Acquisition
2026 Guidance and Organic Growth Outlook
Revenue
$994.23M*
▼ 0.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Charles River Laboratories International, Inc. Q3 FY2025 Earnings Call
Balanced tone
Biotech funding environment
Segment performance trends
Large pharma / global biopharma client spend
Revenue
$1.00B
▼ 0.5% YoY Diluted EPS
$1.10
▼ 17.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Charles River Laboratories International, Inc. Q2 FY2025 Earnings Call
Positive tone
DSA demand stabilization and bookings
Raised full-year financial guidance
FX, tax legislation, and merit increase headwinds
Revenue
$1.03B
▲ 0.6% YoY Diluted EPS
$1.06
▼ 39.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Charles River Laboratories International, Inc. Q1 FY2025 Earnings Call
Balanced tone
FDA NAMs Announcement and Alternative Methods
Biotech Demand Environment
Patient Safety and Scientific Validation
Revenue
$984.17M
▼ 2.7% YoY Diluted EPS
$0.50
▼ 61.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Charles River Laboratories International, Inc. Q4 FY2024 Earnings Call
Cautious tone
DSA segment weakness and pricing pressure
Manufacturing Solutions (RMS) margin expansion
Biotech and global biopharma client demand
Revenue
$1.00B*
▼ 1.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Charles River Laboratories International, Inc. Q3 FY2024 Earnings Call
Cautious tone
DSA and Safety Assessment outlook
Footprint optimization and site consolidation
Restructuring and cost savings
Revenue
$1.01B
▼ 1.6% YoY Diluted EPS
$1.33
▼ 21.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Charles River Laboratories International, Inc. Q2 FY2024 Earnings Call
Cautious tone
DSA demand deterioration
RMS segment outlook
Biotech client trends
Revenue
$1.03B
▼ 3.2% YoY Diluted EPS
$1.74
▼ 7.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Charles River Laboratories International, Inc. Q1 FY2024 Earnings Call
Balanced tone
Manufacturing and RMS segment strength
Demand stabilization and recovery outlook
DSA segment performance and order trends
Revenue
$1.01B
▼ 1.7% YoY Diluted EPS
$1.30
▼ 35.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-14
Charles River Laboratories International, Inc. Q4 FY2023 Earnings Call
Balanced tone
NHP supply mitigation
Demand stabilization outlook
DSA / Safety Assessment headwinds
Revenue
$1.01B*
▼ 7.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Charles River Laboratories International, Inc. Q3 FY2023 Earnings Call
Revenue
$1.03B
▲ 3.8% YoY Diluted EPS
$1.69
▼ 10.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Charles River Laboratories International, Inc. Q2 FY2023 Earnings Call
Revenue
$1.06B
▲ 8.9% YoY Diluted EPS
$1.89
▼ 11.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Charles River Laboratories International, Inc. Q1 FY2023 Earnings Call
Revenue
$1.03B
▲ 12.6% YoY Diluted EPS
$2.01
▲ 11% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Charles River Laboratories International, Inc. Q4 FY2022 Earnings Call
Revenue
$1.10B*
▲ 21.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Charles River Laboratories International, Inc. Q3 FY2022 Earnings Call
Revenue
$989.16M
▲ 10.4% YoY Diluted EPS
$1.88
▼ 6.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Charles River Laboratories International, Inc. Q2 FY2022 Earnings Call
Revenue
$973.13M
▲ 6.4% YoY Diluted EPS
$2.13
▲ 23.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Charles River Laboratories International, Inc. Q1 FY2022 Earnings Call
Revenue
$913.93M
▲ 10.8% YoY Diluted EPS
$1.81
▲ 50.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-16
Charles River Laboratories International, Inc. Q4 FY2021 Earnings Call
Revenue
$905.05M*
▲ 14.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Charles River Laboratories International, Inc. Q3 FY2021 Earnings Call
Revenue
$895.94M
▲ 20.5% YoY Diluted EPS
$2.01
▼ 1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Charles River Laboratories International, Inc. Q2 FY2021 Earnings Call
Revenue
$914.61M
▲ 34% YoY Diluted EPS
$1.72
▲ 28.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Charles River Laboratories International, Inc. Q1 FY2021 Earnings Call
Revenue
$824.57M
▲ 16.6% YoY Diluted EPS
$1.20
▲ 17.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Charles River Laboratories International, Inc. Q4 FY2020 Earnings Call
Revenue
$790.99M
▲ 14.4% YoY Diluted EPS
$2.81
Gross margin
37.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Charles River Laboratories International, Inc. Q3 FY2020 Earnings Call
Revenue
$743.30M
▲ 11.3% YoY Diluted EPS
$2.03
▲ 39% YoY Gross margin
38.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Charles River Laboratories International, Inc. Q2 FY2020 Earnings Call
Revenue
$682.58M
▲ 3.8% YoY Diluted EPS
$1.34
▲ 52.3% YoY Gross margin
34.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Charles River Laboratories International, Inc. Q1 FY2020 Earnings Call
Revenue
$707.06M
▲ 17% YoY Diluted EPS
$1.02
▼ 8.1% YoY Gross margin
35.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-11
Charles River Laboratories International, Inc. Q4 FY2019 Earnings Call
Revenue
$691.14M*
▲ 14.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
1100682
CUSIP
159864107
13F (30d)
534 filings
508 filers
Visit website
Investor relations